Open Targets offers an early assessment of the expected efficacy of a therapeutic intervention for a given drug target, with the aim of improving the almost 90 per cent failure rate of drug discovery efforts in clinical trials. The extensive programme of experimental and informatics projects uses large-scale experiments, analysis, and cutting edge informatics technologies to provide a more complete understanding of the biological drug target. Our projects are designed to identify causal links between targets and disease in three focus areas: oncology, neurodegeneration, and immunology and inflammation, as well as provide disease agnostic informatics frameworks for target identification and prioritisation.
Our research projects have made significant contributions to understanding the relationships between targets and diseases, presented in our series of high-impact research publications.
Details on our resources can be found on our website.
Experimental Cancer Genetics
We are a team of cancer biologists, geneticists and computational biologists interested in understanding how cancers develop and the ways of ...
Genomics of inflammation and immunity
The goal of our research is to use high-throughput screens to gain causal insights into the biological basis of human disease, ...
COSMIC (Catalogue Of Somatic Mutations In Cancer)
Cancer Genome Project
The COSMIC group combines expert cancer scientists with experienced bioinformaticians to build the world's largest database of somatic mutations in ...
Cellular and Gene Editing Research
We develop novel genome editing techniques, cellular differentiation and cellular phenotyping systems, especially with respect to high-throughput investigation of gene and ...
We combine genomic analysis with clinical data to understand how genetics contributes to the variation between patients in their disease severity ...
Translational Cancer Genomics
The Translational Cancer Genomics team investigate how genetic alterations in cancer contribute to disease and impact on response to therapy.
Genomic mutation and genetic disease
The Hurles group studies the genetic causes and mechanisms of rare genetic disorders and how DNA mutates as it is pass ...
Our group studies how normal cell behaviour is altered by mutation in aging and the earliest stages of cancer development. We ...
The Host-Microbiota Interactions Lab explores the relationship between humans and their microbiome- the community of microorganisms that live on and in ...
Understanding human DNA function by engineering
Our goal is to mechanistically understand impact of mutations in human DNA. To do so, we engineer DNA variation in cells, ...
Human Complex Traits
Our research focuses on the application of large-scale genomic analysis to unravel the spectrum of human genetic variation associated with cardiometabolic ...
Gene expression genomics
We use cutting edge single cell genomics technologies and computational methods to understand genes, proteins and cells in human health and ...
The Trynka group combines experimental and computational approaches to study how genetics control the immune system and predispose individuals to autoimmune ...
The Barrett team studied how genetic variation affects risk for diseases, and finds ways to apply that knowledge to improve ...
Genomics of gene regulation
Gene expression involves the transformation of genetic information encoded in DNA sequence into a gene product, such as a protein. Regulation ...
Quantitative models of gene expression
The Hemberg group is interested in developing quantitative models of gene expression. Our approach is theoretical and we strive to develop ...
Related news and blogs
5 Jul 2023
Dr David Hulcoop appointed as Open Targets Director
Open Targets is an innovative public-private partnership that uses human genetics and genomics data to systematically identify and prioritise drug targets
19 Jan 2023
Bowel cancer mutations that impact immunotherapy identified
Researchers used CRISPR and mini tumours to discover more about how cancer develops and responds to the body’s immune response.